22 May 2013
Keywords: R&D resources, Alzheimer's disese,NeuroPerspective
Article | 05 October 2011
A comprehensive review of Alzheimer's therapeutics, and a critical assessment of the pharmaceutical industry's ill-considered allocation of R&D ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 October 2011
6 October 2011
4 October 2011
© 2013 thepharmaletter.com